The global molecular imaging market is witnessing steady growth as healthcare providers increasingly adopt advanced diagnostic technologies to enable earlier disease detection and improve patient outcomes. Valued at USD 8.92 billion in 2025, the market is projected to reach USD 12.94 billion by 2034, expanding at a CAGR of 4.22% during the forecast period.
Molecular imaging has become an essential component of modern healthcare by allowing clinicians to visualize biological processes at the cellular and molecular levels before structural abnormalities become apparent. The technology plays a critical role in oncology, cardiology, neurology, and drug development while supporting the growing shift toward precision medicine. Continuous innovation in hybrid imaging systems, artificial intelligence, and radiopharmaceuticals is further strengthening market expansion worldwide.
- Market Size (2025): USD 8.92 Billion
- Market Size (2026): USD 9.30 Billion
- CAGR (2026–2034): 4.22%
- Forecast Year: 2034
- Projected Market Size (2034): USD 12.94 Billion
- Dominant Region: North America
- Fastest Growing Region: Asia Pacific
Market Overview
The molecular imaging market continues to evolve as healthcare systems prioritize early diagnosis, personalized treatment strategies, and non-invasive imaging technologies. PET, SPECT, PET/CT, PET/MRI, and other hybrid imaging platforms are becoming increasingly valuable in detecting diseases at earlier stages, monitoring treatment response, and supporting clinical research.
Growing investments in diagnostic infrastructure, rising incidence of chronic diseases, expanding use of radiopharmaceuticals, and government support for medical imaging innovation are accelerating global market development. As healthcare providers seek more accurate and efficient diagnostic tools, molecular imaging remains a cornerstone of precision healthcare.
Growth Drivers
The increasing prevalence of chronic diseases is a major factor fueling market growth. Rising cases of cancer, cardiovascular disorders, neurological diseases, and diabetes have intensified the demand for advanced imaging technologies capable of providing highly accurate diagnostic information.
Artificial intelligence is also reshaping molecular imaging by improving image reconstruction, automating image interpretation, reducing scan times, and enhancing diagnostic confidence. AI-powered PET and CT platforms are enabling clinicians to detect abnormalities faster while improving workflow efficiency across hospitals and diagnostic centers.
Furthermore, expanding applications in pharmaceutical research and clinical trials continue to increase demand for molecular imaging technologies used to evaluate disease progression and therapeutic effectiveness.
Market Challenges
Despite favorable growth prospects, the high cost of molecular imaging equipment remains a significant challenge. PET/CT, PET/MRI, and SPECT systems require substantial capital investments, specialized infrastructure, ongoing maintenance, and trained professionals.
Limited reimbursement policies in several countries and restricted access to advanced imaging technologies in developing regions also constrain widespread market adoption.
Emerging Opportunities
Hybrid imaging systems represent one of the most promising growth opportunities for the industry. Integrated technologies such as PET/CT and PET/MRI provide both functional and anatomical information, enabling physicians to make more accurate diagnoses while improving treatment planning.
Continuous innovation in digital detectors, AI-assisted imaging, and advanced radiopharmaceuticals is expected to create new opportunities across oncology, cardiology, neurology, and precision medicine applications. Growing healthcare investments across emerging economies are also opening new avenues for market expansion.
Segment Analysis
Single Photon Emission Computed Tomography (SPECT) systems continue to account for the largest market share owing to their cost-effectiveness, widespread clinical adoption, and versatility across multiple diagnostic applications.
Among applications, oncology remains the leading revenue-generating segment as molecular imaging plays a vital role in tumor detection, staging, therapy monitoring, and recurrence evaluation. The increasing use of targeted radiopharmaceuticals and hybrid imaging systems further strengthens the segment's leadership.
Hospitals dominate the end-user segment due to their advanced imaging infrastructure, multidisciplinary healthcare teams, and greater investment capacity for high-end diagnostic technologies.
Regional Analysis
North America continues to lead the global molecular imaging market, supported by advanced healthcare infrastructure, strong research funding, widespread adoption of hybrid imaging systems, and significant investments in artificial intelligence-based diagnostics. The region also benefits from a strong presence of leading medical imaging companies and continuous technological innovation.
Asia Pacific is projected to register the fastest growth throughout the forecast period. Expanding healthcare infrastructure, rising chronic disease burden, growing nuclear medicine facilities, increasing government healthcare spending, and greater adoption of precision diagnostics are accelerating market development across countries such as China and India.
Europe also demonstrates strong growth potential, supported by healthcare modernization initiatives, increasing use of PET/CT and SPECT/CT technologies, and growing investments in radiopharmaceutical research.
Competitive Landscape
Leading companies continue to strengthen their market positions through technological innovation, AI integration, strategic collaborations, product launches, and investments in hybrid imaging systems.
Key market players include:
- Siemens Healthineers
- GE Healthcare
- Koninklijke Philips N.V.
- Bruker Corporation
- Fujifilm Holdings Corporation
- Canon Medical Systems Corporation
- Mediso Ltd.
- PerkinElmer Inc.
- MILabs B.V.
Recent Developments
- May 2025: Siemens Healthineers expanded its molecular imaging portfolio with advancements in PET/CT and SPECT technologies to improve diagnostic accuracy and workflow efficiency.
- June 2025: GE HealthCare enhanced its PET imaging platforms with advanced digital technologies to improve image quality, quantitative analysis, and clinical workflows.
- July 2025: United Imaging Healthcare introduced new PET/CT system developments to strengthen its oncology, neurology, and cardiovascular imaging capabilities.
- September 2025: Koninklijke Philips expanded its molecular imaging portfolio through advancements in PET/MR and digital imaging technologies supporting personalized treatment planning.
Click to Read the Complete Insights & Report:https://straitsresearch.com/report/molecular-imaging-market
Future Outlook
The molecular imaging market is expected to maintain stable long-term growth as healthcare providers increasingly embrace precision medicine, AI-powered diagnostics, and hybrid imaging technologies. Rising investments in healthcare infrastructure, expanding clinical research activities, growing adoption of radiopharmaceuticals, and continuous technological advancements will continue to strengthen market opportunities worldwide. As early diagnosis becomes increasingly important in managing chronic diseases, molecular imaging will remain an indispensable technology for improving clinical outcomes and enabling personalized healthcare.
About Straits Research
Straits Research is a global market intelligence and consulting company that delivers actionable research, analytics, and advisory services across diverse industries. The company provides comprehensive market reports, competitive intelligence, customized research solutions, and strategic insights that empower organizations to make informed business decisions. With a commitment to accuracy, innovation, and client success, Straits Research helps businesses identify emerging opportunities, evaluate market trends, and achieve sustainable growth in an evolving global marketplace.